Novo buys rights to Chinese weight-loss pill in $2.6bn deal
The Danish firm acquires the drug from Hengrui Pharma, which could potentially be taken just once a week.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
This story has stopped developing; this page is its permanent record. More from that day
The story so far
2 publishers have covered this in 3 articles since 29 Sept 2026. News Feed published first, on 29 September at 08:41 UTC; STAT followed 4h 43m later. The most recent article, from News Feed, appeared on 30 September at 14:11 UTC.
Outlets reporting it: News Feed (major outlet), STAT.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
How it unfolded
Every source in the order it published.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- Novo
- Hengrui Pharma